Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nivolumab safe and effective for cancer patients with HIV

Gobert et al. ESMO 2018, Abstract 1213P_PR.

Key clinical point: Patients with HIV who are treated with nivolumab, a programmed death-1 (PD-1) inhibitor, appear to have similar safety and efficacy outcomes compared with HIV-negative patients treated with the same agent.

Major finding: No immune-related adverse events or deaths due to drug toxicity occurred.

Study details: A retrospective analysis of 20 patients with HIV who received nivolumab immunotherapy.

Disclosures: Jean-Philippe Spano, principal investigator, disclosed relationships with Gilead, Roche, BMS, and others.

Read the article.

Citation:

Gobert et al. ESMO 2018, Abstract 1213P_PR.

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Immuno-oncology

NEO-PV-01 vaccine shows good tolerability and safety , Hu-Lieskovan S et al. SITC 2018, Abstract 07.

Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392

Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514